Abstract
Treatment options for epithelial ovarian cancers are under constant evolution. Recent advances have occurred in both first-line and second-line chemotherapeutic regimens. A newly published approach to first-line therapy incorporating intraperitoneal chemotherapy has demonstrated a benefit in selected patients. There are several new drugs showing activity in platinum- resistant epithelial ovarian cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 29-32 |
| Number of pages | 4 |
| Journal | Current Opinion in Obstetrics and Gynecology |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1998 |
Keywords
- Antineoplastic Agents, Phytogenic/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Carboplatin/administration & dosage
- Carcinoma/drug therapy
- Dose-Response Relationship, Drug
- Female
- Humans
- Injections, Intraperitoneal
- Neoplasm Staging
- Ovarian Neoplasms/drug therapy
- Paclitaxel/administration & dosage
- Treatment Outcome
Fingerprint
Dive into the research topics of 'Modern treatment options in epithelial ovarian carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver